A Phase 1 Study To Evaluate The Effect Of Dimebon On The Pharmacokinetics Of Dextromethorphan

Completed · Phase 1

Conditions studied: Huntington Disease, Alzheimer Disease

In brief

This drug-drug interaction study is being conducted to evaluate the potential effect of Dimebon on the pharmacokinetics on dextromethorphan, a probe substrate of the cytochrome P450 2D6 (CYP2D6) enzyme, after multiple dose administration to healthy adult subjects.

Key facts

Study ID

NCT00788047

Run by

Pfizer

People needed

14

Starts

2008-11-01

Expected to finish

2009-01-01

Last updated by the study team

2009-03-09

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy adult subjects.
• Extensive or ultra-rapid metabolizers of CYP2D6 substrates, predicted by genotype.

You may not qualify if…

• Existence of significant medical conditions that would impact study results or pose unacceptable risks to study subjects.
• Pregnant or nursing females or females of childbearing potential who are unwilling or unable to use an acceptable method of contraception.
• Use of prescription or nonprescription drugs and dietary supplements within 7 days prior to the first dose of study medication.

Where it is running

• Pfizer Investigational Site — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.